Xenon Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 20 analysts polled by S&P Global, Xenon Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $80.56. The average 1-year stock price forecast is 47.03% higher than the current stock price, while the lowest is $63 (+14.98%) and the highest is $100 (+82.52%).

Price Target: $80.56 (+47.03%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$63	$80.56	$80	$100
Change	+14.98%	+47.03%	+46.01%	+82.52%

Analyst Ratings

The average analyst rating for Xenon Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	17	18	17	17	17	17
Buy	3	3	3	3	3	3
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	20	21	20	20	20	20

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Benjamin Burnett Wells Fargo	Wells Fargo	Buy Maintains $69	Buy	Maintains	$69	+25.94%	Jun 2, 2026
Tessa Romero J.P. Morgan	J.P. Morgan	Buy Reiterates $80 → $82	Buy	Reiterates	$80 → $82	+49.66%	May 27, 2026
Cory Kasimov Evercore ISI	Evercore ISI	Buy Maintains $55 → $80	Buy	Maintains	$55 → $80	+46.01%	May 8, 2026
Laura Chico Wedbush	Wedbush	Buy Maintains $63	Buy	Maintains	$63	+14.98%	May 8, 2026
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $80 → $82	Buy	Maintains	$80 → $82	+49.66%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

2.07M

from 7.50M

-72.46%

from 7.50M

Revenue Next Year

35.17M

from 2.07M

1,602.70%

from 2.07M

EPS This Year

-4.81

from -4.36

EPS Next Year

-5.01

from -4.81

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	18.44M	9.43M	-	-	7.50M	2.07M
Revenue Growth	-42.68%	-48.83%	-	-	-	-72.46%
Gross Profit	-57.03M	-96.33M	-167.51M	-210.39M	-293.44M	2.07M
Gross Margin	-309.30%	-1,021.13%	-	-	-3,912.51%	100.00%
Operating Income	-78.99M	-129.14M	-214.05M	-279.30M	-373.07M	-463.35M
Net Income	-78.88M	-125.37M	-182.39M	-234.33M	-345.91M	-440.61M
EPS	-	-	-	-	-4.36	-4.81
Free Cash Flow	-43.76M	-54.30M	-99.88M	-117.59M	-175.08M	-304.75M
No. Analysts	-	-	-	-	-	17

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	22.6M
Avg	2.1M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	201.5%
Avg	-72.5%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-4.81
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-